WO2019058261A9 – July 4, 2019 – SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS

Please complete the required fields.




Inventors :

GUTTERMAN, Donna - 10409 Veasey Mill Road, Raleigh, North Carolina 27615; SEBREE, Terri - 922 Merion Square Road, Gladwyne, Pennsylvania 19035; SMITH, Ted - P.O. Box 4709, Tubac, Arizona 85646; MESSENHEIMER, John - 55 Hermitage Lane, Moncure, North Carolina 27599

Owner :

ZYNERBA PHARMACEUTICALS, INC.

Application Number :

WOIB18057189

Document Number :

WO2019058261A9

Priority Date :

January 1, 1970

Filing Date :

September 18, 2018

Date of Grant/ Publication :

July 4, 2019

Class :

A61K45 / 06; A61K31 / 352; A61P25 / 08

Abstract

The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.

Claim(s)

1, Randomized, Double-Blind, Placebo-Controlled Studies”, Res. Lancet Neurol,;
2 December 2016 (2016-12-02), pages 85-92,;
??055535076,;
Retrieved from the Internet:;
URL:http://zynerba.com/wp-content/upl oads/;
2016/12/????02 AES-2016 Safety Poster ?4-3;
-FINAL-.pdf;
[retrieved on 2018-12-14];
the whole document;
? WO 2010/127033 ?1 (ALLTRANZ INC [US]; 1-28;
STINCHCONB AUDRA LYNN [US]; BANKS STAN LEE;
[US]) 4 November 2010 (2010-11-04);
cited in the application;
abstract ? GB 2 541 191 A (GW PHARMA LTD [GB]) 1-28

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login